KB111

Drug

Related News

Krystal Biotech reports Q1 2026 progress on KB803, KB801 and VYJUVEK expansion

May 04, 2026

Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.

Krystal Biotech Reports Q4 Revenue of $107.1M, Expands International Presence

Mar 20, 2026

Krystal Biotech posted Q4 2025 net revenue of $107.1 million from Vyjuvek sales, with full-year revenue reaching $389.1 million. The company expanded to over 90 patients across Germany, France, and Japan while advancing its pipeline with new FDA designations.